January 12, 2017 04:40 AM EST

CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns

John Carroll

Editor & Founder

CureVac’s leading mRNA program CV9104, a prostate cancer vaccine, has failed a critical Phase IIb study. And that stinging setback for the most advanced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Cure­Vac’s lead mR­NA pro­gram flunks a crit­i­cal PhI­Ib study, rais­ing ques­tions for high-pro­file biotech uni­corns

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns